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Approximately 20,000 hematopoietic cell transplantation (HCT) procedures are performed in the United
States annually. With advances in transplantation technology and supportive care practices, HCT has become
safer, and patient survival continues to improve over time. Indications for HCT continue to evolve as research
reﬁnes the role for HCT in established indications and identiﬁes emerging indications where HCT may be
beneﬁcial. The American Society for Blood and Marrow Transplantation (ASBMT) established a multiple-
stakeholder task force consisting of transplant experts, payer representatives, and a patient advocate to
provide guidance on “routine” indications for HCT. This white paper presents the recommendations from the
task force. Indications for HCT were categorized as follows: (1) Standard of care, where indication for HCT is
well deﬁned and supported by evidence; (2) Standard of care, clinical evidence available, where large clinical
trials and observational studies are not available but HCT has been shown to be effective therapy; (3)
Standard of care, rare indication, for rare diseases where HCT has demonstrated effectiveness but large
clinical trials and observational studies are not feasible; (4) Developmental, for diseases where preclinical
and/or early phase clinical studies show HCT to be a promising treatment option; and (5) Not generally
recommended, where available evidence does not support the routine use of HCT. The ASBMT will periodi-
cally review these guidelines and will update them as new evidence becomes available.
 2015 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).edgments on page 1868.
equests: Navneet S. Majhail, MD, MS,
am, Cleveland Clinic, 9500 Euclid Ave.,
g (N.S. Majhail).
15.07.032
ty for Blood and Marrow Transplantation. Publi
g/licenses/by-nc-nd/4.0/).INTRODUCTION
Hematopoietic stem cell transplantation (HCT) using he-
matopoietic progenitor cells from the patient (autologous
HCT) or a donor (allogeneic HCT) is a potentially curative
therapy for many life-threatening cancers and nonmalignant
disorders. Approximately 20,000 HCTs are performed in
the United States each year [1]. The number of annualshed by Elsevier Inc. This is an open access article under the CC BY-NC-ND
Table 1
List of Evidence-Based Reviews Performed by the ASBMT
Review Year Published
Acute myeloid leukemia in children [12] 2007
Acute myeloid leukemia in adults [13] 2008
Myelodysplastic syndrome [14] 2009
Follicular lymphoma [15] 2010
Diffuse large B cell lymphoma [16] 2011
Acute lymphoblastic leukemia in children [17] 2012
Acute lymphoblastic leukemia in adults [18] 2012
Multiple myeloma [19] 2015
Hodgkin lymphoma [20] 2015
Available at: www.asbmt.org/?page¼GuidelineStatements.
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vancements in the ﬁeld of HCT [2], such as routine use of
reduced-intensity conditioning regimens, which allows HCT
in older patients who have a high incidence of hematologic
malignancies; emerging indications for HCT; and introduc-
tion of alternative graft sources such that nearly all patients
who need a transplant now have a donor. At the same time,
early and long-term HCT outcomes continue to improvewith
signiﬁcant improvements in patient selection for HCT,
transplantation technology, and preventive and supportive
care practices [3-6].
The American Society for Blood and Marrow Trans-
plantation (ASBMT), in response to a need identiﬁed by pa-
tients, providers, payers, and policymakers, established a
Task Force to provide guidance on indications for HCT, that is,
which indications may be considered as routine care versus
indications where evidence is emerging or insufﬁcient. The
Task Force consisted of clinical experts, payers, and patient
advocates and was charged with providing consensus
guidelines for clinically appropriate indications for HCT
based on best prevailing evidence. This white paper presents
the recommendations from the Task Force.
GENERAL PRINCIPLES
This article is intended to serve as a guide to the current
consensus on the use of HCT to treat a speciﬁc indication,
both within and external to the clinical trial setting. The Task
Force emphasizes that the guidelines should not be used to
determine whether HCT should be pursued as a treatment
for an individual patient. Whether or not to proceed with
transplantation in an individual patient is a clinical decision
best made between the patient and his or her provider after a
careful consideration of the alternatives, risks, and beneﬁts
of the procedure. The Task Force recognizes that most
transplant centers have a regular forum (eg, tumor board or
patient selection/care conference) where HCT as a treatment
option for individual patients is discussed. However, this
document may serve as a foundation for discussion among
patients, providers, payers, and policymakers regarding
coverage for HCT for speciﬁc indications.
The following guiding principles were followed by the
Task Force in the development of these guidelines:
 The medical decision-making process for a transplant
procedure is complex and includes several factors be-
sides the underlying indication for transplantation.
Some examples of such variables include patient’s
overall health and performance status, comorbidities,
disease risk/status (eg, remission state and respon-
siveness to treatment), and graft and donor source.
Clinicians routinely consider such factors when evalu-
ating a patient with a speciﬁc indication for HCT.
 Recommendations for some diagnoses consider disease
risk (eg, cytogenetics inacute myeloid leukemia and
acute lymphoblastic leukemia). Disease risk is not
deﬁned as a part of this guidance document, and cli-
nicians are instead referred to other guidelines such as
those proposed by the National Comprehensive Cancer
Network (NCCN; www.nccn.org).
 For the purposes of these guidelines, the deﬁnition of
HCT as proposed by the ASBMT and the National
Marrow Donor Program/Be The Match was followed
[7,8]. HCT is deﬁned as an episode of care startingwith a
preparative regimen and continuing through hemato-
poietic stem cell infusion and recovery. Hematopoieticstem cell infusion is the infusion of a product (bone
marrow, peripheral blood stem cells, cord blood) that
contains hematopoietic progenitor cells, often charac-
terized by CD34 expression.
 The European Group for Blood and Marrow Trans-
plantation (EBMT) and the British Society of Blood and
Marrow Transplantation (BSBMT) have published rec-
ommendations for HCT indications [9,10]. The EBMT
and BSBMT guidelines were reviewed in the process of
developing ASBMT guidelines.
 The Task Force considered a formal systematic evidence
review of the literature but determined that it would
not be feasible in the process of formulating our
expansive guidelines. Clinical trials and observational
studies generally focus on speciﬁc questions within a
disease or a group of diseases (eg, comparing outcomes
in a subset of patients with a disease or investigating
approaches for preventing relapse and minimizing
morbidity and mortality of transplantation). Extrapo-
lating the evidence to broad indication categories
would be challenging. In general, for indications cate-
gorized as “Standard of care,” “Standard of care, clinical
evidence available,” or “Standard of care, rare indica-
tion” (see below), the level of evidence and consensus
was comparable with NCCN category 2A recommen-
dation (“Based upon lower-level evidence, there is
uniform consensus that the intervention is appro-
priate”) [11]. All NCCN recommendations are category
2A, unless otherwise noted.
 Where available, published systematic evidence re-
views or guidelines were used as the basis for our
recommendations for categorizing indications. The
ASBMT has published evidence-based reviews for
several indications (Table 1). Similarly, other organiza-
tions have addressed the use of HCT for various in-
dications (eg, NCCN guidelines and position papers
from the ASBMT Practice Guidelines Committee, Center
for International Blood and Marrow Transplant
Research [CIBMTR] working committees and/or EBMT
working parties).
 Overall, the recommendations are based on best avail-
able evidence from clinical trials or, where clinical trials
are not available, registry, multicenter, or single-center
observational studies. A Supplementary Appendix lists
key references on individual indications for HCT.
Although the list is not exhaustive, the references
highlight evidence that was partly used as the basis for
our recommendations.
 The guidelines focus on generally agreed on indications
for the HCT procedure itself and do not go into other
speciﬁc aspects of transplantation considered to be
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recommendations on type of conditioning regimen,
graft-versus-host disease prophylaxis regimen, donor
source, and graft source or recommendations on use of
post-HCT maintenance therapy for speciﬁc indications.
Readers are referred to other published systematic ev-
idence reviews and guidelines for this information.
 The Task Force recommendations are not designed
to deﬁne comprehensive insurance beneﬁts for HCT.
Another ASBMT white paper provides recommenda-
tions on deﬁning a standard episode of care for HCTand
provides guidance on a general approach to coverage
for indications of HCT [8]. Our guidelines can comple-
ment the evidence review that payers conduct as part
of their technology assessment to determine coverage
policies.
 These guidelines will supplement the Referral Guide-
lines: Recommended Timing for Transplant Consultation,
developed jointly by the ASBMT and National Marrow
Donor Program/Be The Match [21].RARE DISEASES
Where sufﬁcient evidence from large studies was not
available (eg, rare diseases), nonanalytic studies and expert
opinion were used, and the recommendations represent
prevalent routine clinical practice for those indications.
Rather than provide a long and evolving list of unique
rare diseases, the indication tables showa concise categorical
list together with selected unique diagnoses for which
transplant is most frequently offered (Tables 2 and 3). It is
recognized that there is a large number of rare disorders for
which transplantation may be used, and the appropriateness
of HCT may depend on the phenotype and the degree of
progression of the disease in an individual patient. To
address these scenarios in their entirety is beyond the scope
of this report. Gathering additional data in these situations
will be important to better understand the beneﬁts and
limits of transplantation. Towards this goal and when
possible, multi-institutional studies will prove important,
preferably in centers with expertise in assessing disease-
speciﬁc outcomes. For rare indications, providers are
advised to discuss with individual patients the risks and
beneﬁts of the HCT procedure while considering the avail-
able literature and clinical experience.
DONOR AND GRAFT SOURCE IN PATIENT SELECTION FOR
HCT
In the present era, a suitable donor source can be found
for most patients who may beneﬁt from HCT [22]. Several
clinical factors have to be considered when determining the
optimal donor and graft source for a given patient, including
but not limited to underlying disease, disease stage, and the
urgency with which transplantation needs to be pursued.
For example, a speciﬁc donor and graft source may not be
suitable for some patients (eg, umbilical cord blood is not
recommended as a donor/graft source for patients with
myeloﬁbrosis unless pursued as part of a clinical trial).
Although HLA-identical sibling donor remains the preferred
donor source, survival after transplantation is comparable
among patients receiving hematopoietic progenitor cells
from HLA-identical sibling and matched unrelated donors
for several diseases [23-31]. Similarly, studies show that
survival after umbilical cord blood transplantation is similar
to other graft sources, and emerging data demonstrateacceptable outcomes with haploidentical donor trans-
plantation [32-41].
The literature on donor and graft sources continues to
evolve rapidly over time. With this background, the Task
Force did not differentiate recommendations for transplant
indications based on donor source (ie, related donor, unre-
lated donor, umbilical cord blood, or haploidentical donor) or
graft source (ie, bone marrow, peripheral blood stem cells, or
umbilical cord blood). This is in contrast to guidelines pub-
lished by the EBMT and BSBMT. Nonetheless, the Task Force
recognizes that donor and graft sources are important con-
siderations when determining the risks and beneﬁts of HCT
for an individual patient.
AGE IN PATIENT SELECTION FOR HCT
Age by itself should not be a contraindication to trans-
plantation in patients who may beneﬁt from this procedure.
Selected older patients with limited comorbidities and good
functional status can safely receive HCT with a relatively low
and acceptable risk of nonrelapse mortality [42-44]. Instead
of chronologic patient age, evaluations such as functional
status, HCT-speciﬁc comorbidity index score, EBMT risk
score, and Pre-transplantation Assessment of Mortality risk
score can assist in determining risks of nonrelapse mortality
and transplant candidacy for individual patients.
DEFINITIONS FOR CLASSIFYING INDICATIONS
The deﬁnitions for categorizing indications for trans-
plantation are presented below. Tables 2 and 3 list the rec-
ommendations for HCT in pediatric and adult diseases.
Standard of Care (S)
This category includes indications that are well deﬁned
and generally supported by evidence in the form of high-
quality clinical trials and/or observational studies (eg,
through the CIBMTR or EBMT).
Standard of Care, Clinical Evidence Available (C)
This category includes indications for which large clinical
trials and observational studies are not available. However,
HCT has been shown to be an effective therapy with accept-
able risk of morbidity and mortality in sufﬁciently large sin-
gle- or multicenter cohort studies. HCTcan be considered as a
treatment option for individual patients after careful evalu-
ation of risks and beneﬁts. As more evidence becomes
available, some indications may be reclassiﬁed as “S.”
Standard of Care, Rare Indication (R)
Indications included in this category are rare diseases for
which clinical trials and observational studies with sufﬁcient
number of patients are not currently feasible because of their
very low incidence. However, single- or multicenter or reg-
istry studies in relatively small cohorts of patients have
shown HCT to be effective treatment with acceptable risks of
morbidity and mortality. For patients with diseases in this
category, HCT can be considered as a treatment option for
individual patients after careful evaluation of risks and
beneﬁts.
Developmental (D)
Developmental indications include diseases where pre-
clinical and/or early phase clinical studies show HCT to be a
promising treatment option. HCT is best pursued for these
indicationsaspart of a clinical trial. Asmore evidencebecomes
available, some indications may be reclassiﬁed as “C” or “S.”
Table 2
Indications for HCT in Pediatric Patients (Generally Age < 18 years)
Indication and Disease Status Allogeneic
HCT
Autologous
HCT
Acute myeloid leukemia
CR1, low risk N N
CR1, intermediate risk C N
CR1, high risk S N
CR2þ S N
Not in remission C N
Acute promyelocytic leukemia, relapse R R
Acute lymphoblastic leukemia
CR1, standard risk N N
CR1, high risk S N
CR2 S N
CR3þ C N
Not in remission C N
Chronic myeloid leukemia
Chronic phase C N
Accelerated phase C N
Blast phase C N
Myelodysplastic syndromes
Low risk C N
High risk S N
Juvenile myelomonocytic leukemia S N
Therapy related S N
T cell non-Hodgkin lymphoma
CR1, standard risk N N
CR1, high risk S N
CR2 S N
CR3þ C N
Not in remission C N
Lymphoblastic B cell non-Hodgkin
lymphoma (non-Burkitt)
CR1, standard risk N N
CR1, high risk S N
CR2 S N
CR3þ C N
Not in remission C N
Burkitt’s lymphoma
First remission C C
First or greater relapse, sensitive C C
First or greater relapse, resistant C N
Hodgkin lymphoma
CR1 N N
Primary refractory, sensitive C C
Primary refractory, resistant C N
First relapse, sensitive C C
First relapse, resistant C N
Second or greater relapse C C
Anaplastic large cell lymphoma
CR1 N N
Primary refractory, sensitive C C
Primary refractory, resistant C N
First relapse, sensitive C C
First relapse, resistant C N
Second or greater relapse C C
Solid tumors
Germ cell tumor, relapse D C
Germ cell tumor, refractory D C
Ewing’s sarcoma, high risk or relapse D S
Soft tissue sarcoma, high risk or relapse D D
Neuroblastoma, high risk or relapse D S
Wilms’ tumor, relapse N C
Osteosarcoma, high risk N C
Medulloblastoma, high risk N C
Other malignant brain tumors N C
Nonmalignant diseases
Severe aplastic anemia, new diagnosis S N
Severe aplastic anemia, relapse/refractory S N
Fanconi’s anemia R N
Dyskeratosis congenita R N
Blackfan-Diamond anemia R N
Sickle cell disease C N
Thalassemia S N
(Continued)
Table 2
(continued)
Indication and Disease Status Allogeneic
HCT
Autologous
HCT
Congenital amegakaryocytic
thrombocytopenia
R N
Severe combined immunodeﬁciency R N
T cell immunodeﬁciency, SCID variants R N
Wiskott-Aldrich syndrome R N
Hemophagocytic disorders R N
Lymphoproliferative disorders R N
Severe congenital neutropenia R N
Chronic granulomatous disease R N
Other phagocytic cell disorders R N
IPEX syndrome R N
Juvenile rheumatoid arthritis D R
Systemic sclerosis D R
Other autoimmune and immune
dysregulation disorders
R N
Mucopolysaccharoidoses (MPS-I and
MPS-VI)
R N
Other metabolic diseases R N
Osteopetrosis R N
Globoid cell leukodystrophy (Krabbe) R N
Metachromatic leukodystrophy R N
Cerebral X-linked adrenoleukodystrophy R N
N indicates not generally recommended; C, standard of care, clinical evi-
dence available; S, standard of care; R, standard of care, rare indication; D,
developmental; CR1, ﬁrst complete response; CR2, second CR; CR3, third CR;
SCID, Severe combined immunodeﬁciency; IPEX, Immune dysregulation,
polyendocrinopathy, enteropathy, X-linked; MPS, mucopolysaccharidosis.
Rather than provide a long and evolving list of unique rare diseases, this
table shows a concise categorical list together with selected unique di-
agnoses for which transplant is most frequently offered. See text for deﬁ-
nition of recommendation categories.
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Transplantation is not currently recommended for these
indications where evidence and clinical practice do not
support the routine use of HCT. The effectiveness of non-
transplant therapies for an earlier phase of a disease does not
justify the risks of HCT. Alternatively, a meaningful beneﬁt
is not expected from the procedure in patients with an
advanced phase of a disease. However, this recommendation
does not preclude investigation of HCT as a potential treat-
ment, and transplantation may be pursued for these in-
dications within the context of a clinical trial.
DATA REPORTING TO CIBMTR
US transplant centers report clinical and outcomes data on
all allogeneic HCT procedures, and most centers report data
on autologous HCT procedures to the CIBMTR. This data
reporting and capture is critical to understanding appropriate
indications for HCT and its utilization and patient outcomes.
PROCESS FOR UPDATING GUIDELINES
The Task Force recognizes the need for periodically
updating these guidelines to keep abreast with ongoing
research in the ﬁeld. New evidence may result in inclusion of
new indications not previously recognized or may lead to
reclassiﬁcation of recommendation category for an existing
indication. The ASBMT’s Practice Guidelines Committee will
periodically review these guidelines and update them as
necessary, with a minimum of once every 2 years.
PUBLIC COMMENTS
The draft manuscript was reviewed by the ASBMT’s
Practice Guidelines Committee and was posted on ASBMT’s
Table 3
Indications for HCT in Adults (Generally Age  18 years)
Indication and Disease Status Allogeneic
HCT
Autologous
HCT
Acute myeloid leukemia
CR1, low risk N C
CR1, intermediate risk S C
CR1, high risk S C
CR2 S C
CR3þ C C
Not in remission C N
Acute promyelocytic leukemia
CR1 N N
CR2, molecular remission C S
CR2, not in molecular remission S N
CR3þ C N
Not in remission C N
Relapse after autologous transplant C N
Acute lymphoblastic leukemia
CR1, standard risk S C
CR1, high risk S N
CR2 S C
CR3þ C N
Not in remission C N
Chronic myeloid leukemia
Chronic phase 1, TKI intolerant C N
Chronic phase 1, TKI refractory C N
Chronic phase 2þ S N
Accelerated phase S N
Blast phase S N
Myelodysplastic syndromes
Low/intermediate-1 risk C N
Intermediate-2/high risk S N
Therapy-related AML/MDS
CR1 S N
Myeloﬁbrosis and myeloproliferative
diseases
Primary, low risk C N
Primary, intermediate/high risk C N
Secondary C N
Hypereosinophilic syndromes, refractory R N
Plasma cell disorders
Myeloma, initial response D S
Myeloma, sensitive relapse C S
Myeloma, refractory C C
Plasma cell leukemia C C
Primary amyloidosis N C
POEMS syndrome N R
Relapse after autologous transplant C C
Hodgkin lymphoma
CR1 (PET negative) N N
CR1 (PET positive) N C
Primary refractory, sensitive C S
Primary refractory, resistant C N
First relapse, sensitive S S
First relapse, resistant C N
Second or greater relapse C S
Relapse after autologous transplant C N
Diffuse large B cell lymphoma
CR1 (PET negative) N N
CR1 (PET positive) N C
Primary refractory, sensitive C S
Primary refractory, resistant C N
First relapse, sensitive C S
First relapse, resistant C N
Second or greater relapse C S
Relapse after autologous transplant C N
Follicular lymphoma
CR1 N C
Primary refractory, sensitive S S
Primary refractory, resistant S N
First relapse, sensitive S S
First relapse, resistant S N
Second or greater relapse S S
Transformation to high grade lymphoma C S
Relapse after autologous transplant C N
(Continued)
Table 3
(continued)
Indication and Disease Status Allogeneic
HCT
Autologous
HCT
Mantle cell lymphoma
CR1/PR1 C S
Primary refractory, sensitive S S
Primary refractory, resistant C N
First relapse, sensitive S S
First relapse, resistant C N
Second or greater relapse C S
Relapse after autologous transplant C N
T cell lymphoma
CR1 C C
Primary refractory, sensitive C S
Primary refractory, resistant C N
First relapse, sensitive C S
First relapse, resistant C N
Second or greater relapse C C
Relapse after autologous transplant C N
Lymphoplasmacytic lymphoma
CR1 N N
Primary refractory, sensitive N C
Primary refractory, resistant R N
First or greater relapse, sensitive R C
First or greater relapse, resistant R N
Relapse after autologous transplant C N
Burkitt’s lymphoma
First remission C C
First or greater relapse, sensitive C C
First or greater relapse, resistant C N
Relapse after autologous transplant C N
Cutaneous T cell lymphoma
Relapse C C
Relapse after autologous transplant C N
Plasmablastic lymphoma
CR1 R R
Relapse R R
Chronic lymphocytic leukemia
High risk, ﬁrst or greater remission C N
T cell prolymphocytic leukemia R R
B cell, prolymphocytic leukemia R R
Transformation to high grade lymphoma C C
Solid tumors
Germ cell tumor, relapse N C
Germ cell tumor, refractory N C
Ewing’s sarcoma, high risk N C
Breast cancer, adjuvant high risk N D
Breast cancer, metastatic D D
Renal cancer, metastatic D N
Nonmalignant diseases
Severe aplastic anemia, new diagnosis S N
Severe aplastic anemia, relapse/refractory S N
Fanconi’s anemia R N
Dyskeratosis congenita R N
Sickle cell disease C N
Thalassemia D N
Hemophagocytic syndromes, refractory R N
Mast cell diseases R N
Common variable immunodeﬁciency R N
Wiskott-Aldrich syndrome R N
Chronic granulomatous disease R N
Multiple sclerosis N D
Systemic sclerosis N D
Rheumatoid arthritis N D
Systemic lupus erythematosus N D
Crohn’s disease N D
Polymyositis-dermatomyositis N D
TKI indicates tyrosine kinase inhibitor; AML/MDS, acute myelogenous leu-
kemia/myelodysplastic syndrome; POEMS, polyneuropathy, organomegaly,
endocrinopathy, monoclonal gammopathy and skin changes; PET, positron
emission tomography; PR1, ﬁrst partial response.
Rather than provide a long and evolving list of unique rare diseases,
this table shows a concise categorical list together with selected unique
diagnoses for which transplant is most frequently offered. See text for
deﬁnition of recommendation categories.
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based on feedback received by the ASBMT community.
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